Measure bans dismemberment abortionThe state House today approved a plan introduced by Rep. Lynn Afendoulis to protect the dignity of life and unborn children by banning dismemberment abortions in Michigan.A dismemberment abortion is an abortion in which a health care worker intentionally dismembers a living fetus in the uterus in order for it to be extracted. The legislation from Afendoulis is part of a plan to ban the procedure and create penalties for violators.“This is not about our rights as women. This is about our humanity. Where else, in any norm or more or practice or law, is it acceptable to torture and dismember a living thing?” said Afendoulis, of Grand Rapids Township. “This practice is gruesome. It is inhumane. And, outrageously, it is unnecessary. It must stop.”Twelve states already have had legislation signed into law that bans dismemberment abortions.According to data published by the Michigan Department of Health and Human Services, there were 1,777 dismemberment abortions, also called dilation and evacuation abortions, in Michigan in 2017. That is nearly five per day.House Bill 4321 now moves to the Senate for consideration.### Categories: Lynn Afendoulis News 14May House approves Rep. Afendoulis plan to protect the lives of the unborn in Michigan
UK connected TV service YouView has launched a new advertising campaign focusing on the breadth and choice of TV shows and films that are now available oh the service. Based on the tagline ‘Unwrap box sets all year long’, the campaign highlights recent additions to the YouView content line-up including Netflix, Quest OD from Discovery and the re-launched UKTV Play.Launching nationwide on outdoor poster sites including London’s Piccadilly Circus, the campaign also highlights the strong relationships held with YouView’s seven shareholders the BBC, ITV, Channel 4, Channel 5, TalkTalk, BT and Arqiva, who this year committed to five more years of guaranteed funding.Creative for the campaign, which runs until early January, was produced by Albion, while media was planned and bought by OMD.
Mikhail MedrishMoscow-based Russian cable operator Akado has named Mikhail Medrish as director of operations for Komkor, the operator’s consumer-facing brand.Medrish previously headed the Internet Support Foundation, a non-profit organisation dedicated to ensuring the development of the internet in Russia. Prior to taking on that role in 2014 he served as technical director for major internet projects in Russia and was chairman of Russia’s Internet Coordination Centre.Akado/Komkor CEO Sergey Nazarov said that the quality of its network operations was a priority for the company and that the appointment of Medrish would strengthen its efforts in this area.
“The demand for tickets was huge and our Box Office team were inundated with requests for bookings.“Our website also experienced capacity traffic in record numbers.“It’s not surprising, as Kevin is one of the most popular comedians on the circuit at the minute and he has previously enjoyed sell-out gigs at our venue.”The spokeswoman said “many more big acts” will be announced for the Forum “in the near future.” She added: “I would encourage customers to consider joining our Priority Plus Club which will guarantee priority booking for all upcoming shows in advance of general release.”For more information on how to join Priority, contact the Forum Box Office team on 71 264455.” Kevin Bridges.Three shows to be staged in Derry next year by top comic Kevin Bridges sold out within hours of tickets going on sale, Derry Daily can reveal.Tickets, priced £26 for the 17, 18 and 19 July shows at the Millennium Forum, went on sale on Friday morning last, but sold out within a few hours – with record numbers applying online.A spokeswoman for the Forum said: “All three shows for the Kevin Bridges gigs have now completely sold out in within a few hours of going on sale. KEVIN BRIDGES SELLS OUT FORUM “WITHIN A FEW HOURS”: RECORD NUMBERS APPLY ONLINE was last modified: November 24th, 2014 by stephenstephen Tags: ShareTweet bridgesDerryforumkevinmillenniumOUTsold
Reviewed by Alina Shrourou, B.Sc. (Editor)Dec 4 2018Russian researchers announced the development of a combined action drug based on ionizing radiation and bacterial toxin. Their total effect appeared to be 2,200 times stronger compared to that exerted by the radiation and toxin, separately. The drug affects tumor cells selectively providing better diagnostics and treatment of malignant tumors. These advances were reported in an article published in the Proceedings of the National Academy of Sciences.Chemotherapy is widely used for treatment of cancerous diseases. However, it is associated with severe side effects (hair loss, nausea, loss of appetite, oedema, anemia, memory disorders, and so on) as the drugs affect the body in total and are accumulated throughout normal tissues. Moreover, the chemotherapy often requires repeated drug administration to overcome tumor propensity to relapse. A perfect anti-cancer drug should provide a powerful impact to all tumor cells at once to prevent their recovery.The combined therapy proposed and realized by the Russian scientists appeared to be successful. “Just like modern armies deploy tanks, foot troops, and artillery, we also fight tumors using several mechanisms at once: ionizing radiation and a strong toxin of bacterial origin,” says Andrey Zvyagin, head of the Department of Biomedical Engineering at the Institute of Molecular Medicine, Sechenov University.The drug developed by the scientists consists of a nanoparticles, as the core, with embedded radiopharmaceutical agent (a source of ionizing beta-radiation), and a highly toxic toxin derived from bacterium Pseudomonas aeruginosa. The nanosized drug core is decorated with polymer to render the nanocomplex water miscible and biologically amiable and coupled with biological molecules, which represent the toxin fused with a targeting biomolecule by genetic engineering methods. The radiopharmaceutical agent is well secluded inside the nanoparticle and guarantees its side-effect-free targeted action to tumor cells. Blood vessels that feed the tumor have pores through which the drug enters the tumor from the blood flow. The targeting biomolecule binds itself with cancer cells causing them to accumulate in the primary and metastatic tumors. The radiopharmaceutical agent is able to affect the cells both in immediate proximity to the nanoparticles and up to 1 cm from them, providing for efficient therapy of considerable tumor masses. The toxin blocks the synthesis of proteins in the cells preventing them from restoration and dissemination.The new drug was tested both on cells and laboratory animals: breast cancer (the most widely spread type of cancer in women) was grafted on a laboratory mouse, and after that the tested drug was administered to it. In experiments on cells, the effect of the combination was 2,200 times stronger than the effect from the separate use of its components. The efficiency of combined therapy was confirmed by experiments on laboratory mice. The drug not only treats, but also facilitates visualization of the tumors, which makes it a diagnostical tool. The area of medicine that combines diagnostics and treatment is called theranostics. Source:https://www.sechenov.ru/
Source:https://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1258 Reviewed by James Ives, M.Psych. (Editor)Dec 7 2018Even with equivalent treatments in women with hormone receptor-positive, HER2-negative breast cancer, black women had significantly higher breast cancer recurrence and increased overall mortality compared to white women in a large phase III clinical trial, TAILORx, according to data presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.”Our findings are consistent with prior studies indicating that black women with hormone-receptor positive, HER2-negative breast cancer have worse prognoses than women of other racial and ethnic backgrounds, even when they have access to the same contemporary cancer care,” said Kathy Albain, MD, Huizenga Family Endowed Chair in Oncology Research and professor of medicine at Loyola University Chicago Stritch School of Medicine and director of the Breast and Thoracic Oncology Programs at the Cardinal Bernardin Cancer Center of Loyola Medicine in Maywood, Illinois. “This suggests that additional research is required to determine the basis for these racial disparities and also highlights the need to enhance accrual of minority populations in cancer clinical trials.”Albain and colleagues analyzed the association between clinical outcomes and race in participants from the TAILORx trial, which evaluated more than 10,000 women with the most common type of early breast cancer (hormone receptor-positive, HER2-negative, axillary lymph node-negative). Findings released from the TAILORx study in June 2018 showed no benefit from chemotherapy for 70 percent of the women in the trial. It found that treatment to prevent the cancer from returning with chemotherapy and hormone therapy, following surgery, is not more beneficial than hormone therapy alone in patients with a low or intermediate recurrence score.Following enrollment in the TAILORx trial, patients’ tumors were analyzed using the 21-gene Oncotype DX recurrence score (RS; on a scale of 0-100) which predicts cancer recurrence. Patients with low risk (RS score of 0-10) were treated with hormone therapy alone, while patients with high risk (RS score 26 and above) were treated with hormone therapy and chemotherapy. Patients with an intermediate risk of recurrence (RS score of 11-25)–the primary study group–were randomized to receive hormone therapy and chemotherapy or hormone therapy alone.Related StoriesUsing machine learning algorithm to accurately diagnose breast cancerNew study to ease plight of patients with advanced cancerCancer killing capability of lesser-known immune cells identifiedOf the 9,719 breast cancer patients able to be evaluated, 8,189 (84 percent) were white, 693 (7 percent) were black, 405 (4 percent) were Asian, and 432 (4 percent) were of other or unknown race. In terms of ethnicity, 7,635 (79 percent) were non-Hispanic, 889 (9 percent) were Hispanic, and 1,195 (12 percent) were of unknown ethnicity. The trial showed no significant difference in RS distribution or mean RS between white and black participants.Usage and type of chemotherapy following surgery were similar between black and white participants and between Hispanic and non-Hispanic populations. Additionally, the usage, type, and duration of hormone therapy were similar between black and white participants and between Hispanic and non-Hispanic populations.In an analysis of the entire trial population, black women had up to a 4 percent higher absolute risk of recurrence or death. When the authors compared outcomes between black and white women, adjusting for multiple factors, they found that black women had a 39 percent higher relative risk of breast cancer recurrence and a 52 percent higher relative risk of death.Sixty-eight percent of black women in the trial had a RS score of 11-25. In this intermediate group, there was an 80 percent higher relative risk of recurrence in black women compared to white women. There was a 67 percent higher relative risk of death in black women compared to white women.When ethnicity was examined, women of Hispanic ethnicity generally had better outcomes than non-Hispanic women, Albain said.”The racial disparities observed in this trial were not explained by differences in recurrence score, duration, or reported adherence to hormone therapy, nor were they explained by use of chemotherapy, or characteristics such as age, tumor size, or tumor grade,” Albain said. “As such, our results suggest that biological differences may contribute to the significantly different outcomes of black women compared to others with breast cancer.”Limitations of the study include the retrospective nature of the analysis, lack of adequate power to address specific questions in the race/ethnicity subsets, and a reliance on self-reported adherence to hormone therapy.
© 2019 AFP “This certainly has a negative effect on the ability of companies to attract top talent to Japan,” Schulz told AFP.As the Ghosn case has laid bare, Japan’s legal system gives enormous power to prosecutors, who nearly always secure guilty verdicts.Courts routinely allow suspects to be held for questioning for lengthy periods, and many major media outlets are largely supportive of the authorities.”People are worried. It creates a legal uncertainty on the business conditions in Japan,” said another Tokyo-based source with close ties to foreign firms. “Seeing how the system works, and how it is orchestrated in the media, creates anxiety among business leaders, an uneasy feeling,” the person said. Some in the expat business community believe the French-Brazilian-Lebanese tycoon, the once-revered chairman of Nissan, has been the victim of unfair harshness because he is a foreigner.”The way Mr. Ghosn is treated seems completely out of proportion compared to the way Japanese executives are treated,” said one Tokyo-based French businessperson, who asked not to be named.This businessperson pointed to a series of massive accounting scandals at Toshiba during which Japanese executives avoided criminal charges.In contrast, Ghosn has languished in a Tokyo detention centre for more than 50 days as he fights a string of allegations of financial misconduct. The court has banned his family from visiting, allowing only contact with his lawyers and diplomats.”It gives the impression of double standards, as if (Ghosn) was being treated this way because he is a foreigner. I do not see how they are going to attract qualified foreigners,” the person told AFP.”Ghosn was an icon, a symbol of French success and this has poured cold water on quite a few ambitions from young trainees—at least those training for careers in business and management.” Former Nissan chief Carlos Ghosn is fighting a string of allegations of financial misconduct Ghosn’s case has highlighted how the Japanese system differs from western business norms, analysts say Ghosn’s case has also highlighted how the Japanese system differs from western business norms, said corporate compliance lawyer Nobuo Gohara, also a former Tokyo prosecutor.Gohara noted that Nissan’s sitting Chief Executive Officer Hiroto Saikawa did not give Ghosn the opportunity to defend himself internally to the company’s board.Instead, the Nissan management conducted an internal probe, sided with prosecutors and swiftly sacked Ghosn after his arrest.”People see what kind of case this is, and what kind of treatment Mr. Ghosn has received so far,” Gohara told AFP.”If you were a manager with a very high salary in Japan—and because of your compensation, you might find yourself in a situation like that—I would imagine people with normal, common sense would not want to work in Japan,” he said.”You would be too scared.” Ghosn dominates talk in expat business circles Japan court rejects Ghosn release bid The detained executive was initially kept in a tiny room with Japanese-style tatami for sleeping—sparking outrage from abroad. He has now been moved to a larger room and has a Western-style bed, according to his lawyer Motonari Otsuru.But even Otsuru has dampened expectations his client could be released any time soon, suggesting it could be six months until a trial and stressing that bail is unlikely in such cases.’People are worried’Many in Japan have voiced surprise that foreigners have criticised their legal system and prosecutors have reacted angrily, saying they are playing by the rules in place.”This is a specific case,” said Seiji Nakata, head of Daiwa Securities. “I am in contact with foreign bosses and they have not voiced any pessimism on the subject”.But Ghosn dominates talk in expat business circles and while foreign investors are not yet rushing to leave Tokyo, the case has worried executives who fear they may unknowingly face legal troubles even if they think they are operating legally. Explore further The detained executive was initially kept in a tiny room with Japanese-style tatami for sleeping—sparking outrage from abroad Citation: Ghosn case rattles Japan’s expat business community (2019, January 10) retrieved 17 July 2019 from https://phys.org/news/2019-01-ghosn-case-rattles-japan-expat.html “Mr. Ghosn’s case has shone a strong spotlight on the opaqueness of Japan’s prosecution system,” said Martin Schulz, economist at the Fujitsu Research Institute in Tokyo. Carlos Ghosn’s prolonged detention under what critics see as Japan’s opaque and draconian legal system has alarmed foreign executives and sparked questions over the country’s ability to attract overseas talent. This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Dongri building collapse: Man awaits word on whereabouts of wife, sonShamani, who works in Delhi, was visiting his extended family in the four-storey building in Dongri in south Mumbai when it collapsed just before noon Tuesday, killing 11 persons, including 4 women and one child.advertisement Press Trust of India MumbaiJuly 16, 2019UPDATED: July 16, 2019 22:57 IST The 4-storey building in Mumbai collapsed on Tuesday, trapping at least 40 people. (Photo credit: AP)HIGHLIGHTSShamani was visiting his extended family in the old building in Mumbai when it collapsed on TuesdayThe young man worries as even after seven hours his wife Sana, son Ibrahim are untraceableThe incident has killed 11 persons, including 4 women and one child”My mother is seriously injured and other family members, including my wife and son, are still untraceable,” says Nawab Shamani from his hospital bed in a voice that is a mixture of pain and anguish.Shamani, who works in Delhi, was visiting his extended family in the four-storey building in Dongri in south Mumbai when it collapsed just before noon Tuesday, killing 11 persons, including 4 women and one child.While resting on a bed in state-run J J Hospital, Shamani, who is in his 30s, said he could only recall that he was sleeping in a flat in the ill-fated building and suddenly heard a loud thud.”Next thing I remember is I am lying on a hospital bed with some injuries to my head and a hand,” he said.What worries the young man more is that even after seven hours after the mishap, his wife Sana and son Ibrahim are still untraceable.Rescuers at the spot are fighting a battle against time as several people are still feared trapped under the rubble of the unauthorised building which housed 15 families, as per preliminary information.”My mother is seriously injured but she is out of danger. I have informed authorities about my family members but have received no information from them about their whereabouts so far. They are still untraceable even around 6-7 hours after the tragedy,” Shamani said.The approach roads to the spot of the incident are so narrow that even rescue vehicles struggled to make their way.According to National Disaster Response Force (NDRF), the toll has risen to 11, including 4 women and one child.Scores of locals joined in the effort, forming a human chain to help in removing the debris brick by brick and picking up slabs of concrete to locate those buried at the spot.ALSO READ | https://www.indiatoday.in/india/story/mumbai-building-collapse-teenager-rescues-trapped-residents-in-dongri-1570150-2019-07-16ALSO WATCH | Four-storey building collapses in Mumbai, over 40 trappedFor the latest World Cup news, live scores and fixtures for World Cup 2019, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for World Cup news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted byPrakriti Sharma Next